ArticleBMJ open2020
Overview of the burden of chronic kidney disease in Mexico: secondary data analysis based on the Global Burden of Disease Study 2017.
Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Kidney Function and Mortality in Mexico: Prospective Study of 130,000 Adults.Kidney medicine · 2026Article
- Implementation of the AAMATES Platform as a National Registry for Stage 5 CKD in Mexico.Kidney medicine · 2026Article
- Safety and feasibility of initiating peritoneal dialysis within 24 h after percutaneous versus surgical catheter placement.Clinical kidney journal · 2026Article
- Determinants of pediatric urolithiasis hospitalizations in endemic and non-endemic regions of Mexico.Frontiers in urology · 2026Article
- Nanocomposite Polysulfone/CB Modified by Melt Extrusion and Solution Mixing for Enhanced Removal of Uremic Toxins.Materials (Basel, Switzerland) · 2025Article
- Association between advanced glycation end products and estimated glomerular filtration rate: a cross-sectional analysis.Diabetology & metabolic syndrome · 2025Article
- [Association of serum vitamin D and acute renal graft dysfunction].Revista medica del Instituto Mexicano del Seguro Social · 2025Observational
- Vanadium exposure and kidney markers in a pediatric population: a cross-sectional study.Pediatric nephrology (Berlin, Germany) · 2025Article
- [Elevated neutrophil-lymphocyte ratio and delayed graft function].Revista medica del Instituto Mexicano del Seguro Social · 2025Observational
- Inflammation in glomerular diseases.Frontiers in immunology · 2025Review
- Revealing the burden of chronic kidney disease in Mexican women, 1990-2021.BMC nephrology · 2024Article
- Patients Living With Arterial Hypertension in Mexico: First Insights of The Mexican Registry of Arterial Hypertension (RIHTA Study).American journal of hypertension · 2024Article
- Experimental Lab Tests on Rabbits for the Optimization and Redesign of Low-Cost Equipment for Automated Peritoneal Dialysis.Bioengineering (Basel, Switzerland) · 2024Article
- Strategies to prevent, diagnose and treat kidney disease related to systemic arterial hypertension: a narrative review from the Mexican Group of Experts on Arterial Hypertension.BMC nephrology · 2024Review
- Article
- External validation of a minimal-resource model to predict reduced estimated glomerular filtration rate in people with type 2 diabetes without diagnosis of chronic kidney disease in Mexico: a comparison between country-level and regional performance.Frontiers in endocrinology · 2024Observational
- Ten-Year Single-Center Study Examining Patient Survival after Commencing Long-Term Peritoneal Dialysis.Journal of clinical medicine · 2023Article
- Evaluation of hemodialysis vascular access. Perspective from Mexico.Frontiers in nephrology · 2023Article
- Sex Differences in CKD-Associated Mortality From 1990 to 2019: Data From the Global Burden of Disease Study.Kidney medicine · 2022Article
- COVID-19 Pneumonia in Fully Vaccinated Adults during the Dominance of the Omicron Sublineages BA.1.1 and BA.2 in Mexico.Medicina (Kaunas, Lithuania) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the evolution of the burden of chronic kidney disease (CKD) in Mexico by states, sex and subtypes from 1990 to 2017.
designSecondary data analysis based on the Global Burden of Disease Study (GBD) 2017.
participantsMexico and its 32 states. Data were publicly available and de-identified and individuals were not involved.
methodsWe analysed age-standardised mortality rates, years of life lost (YLL) due to premature death, years lived with disability (YLD) and disability-adjusted life years (DALY), as well as the percentage of change of these indicators between 1990 and 2017.
resultsFrom 1990 to 2017, the number of deaths, YLL, YLD and DALY due to CKD increased from 12 395 to 65 033, from 330 717 to 1 544 212, from 86 416 to 210 924 and from 417 133 to 1 755 136, respectively. Age-standardised rates went from 28.7 to 58.1 for deaths (% of change 102.3), from 601.2 to 1296.7 for YLL (% of change 115.7), from 158.3 to 175.4 for YLD (% of change 10.9) and from 759.4 to 1472.2 for DALY (% of change 93.8). The highest burden of CKD was for Puebla and the lowest for Sinaloa. It was also greater for men than women. By subtypes of CKD, diabetes and hypertension were the causes that contributed most to the loss of years of healthy life in the Mexican population.
conclusionsMexico has experienced exponential and unprecedented growth in the burden of CKD with significant differences by states, sex and subtypes. Data from the GBD are key inputs to guide decision-making and focus efforts towards the reduction of inequities in CKD. These results should be considered a valuable resource that can help guide the epidemiological monitoring of this disease and prioritise the most appropriate health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.